Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line

Genomics

Volumn 101, Issue 4, 2013, Pages 213-220

  AbuHammad, Shatha ^a   Zihlif, Malek ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Doxorubicin resistance; Gene expression; MCF7

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; DOXORUBICIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL STRAIN MCF 7; CELL STRUCTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; DNA REPAIR; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MCF-7 CELLS; MEMBRANE TRANSPORT PROTEINS; SELECTION, GENETIC; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84875542642     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2012.11.009     Document Type: Article

References (50)

1. Ferlay J., Shin H.-R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127(12):2893-2917.
2. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56(2):185-229.
3. Sinha B.K., Mimnaugh E.G., Rajagopalan S., Myers C.E. Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance. Cancer Res. 1989, 49(14):3844-3848.
4. Tassone P., Tagliaferri P., Perricelli A., Blotta S., Quaresima B., Martelli M.L., Goel A., Barbieri V., Costanzo F., Boland C.R., Venuta S. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br. J. Cancer 2003, 88(8):1285-1291.
5. Villman K., Sjostrom J., Heikkila R., Hultborn R., Malmstrom P., Bengtsson N.O., Soderberg M., Saksela E., Blomqvist C. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer. Acta Oncol. 2006, 45(5):590-596.
6. Harris J.R., Lippman M.E., Morrow M., Osborne C.K. Treatment of metastatic breast cancer. Diseases of the Breast 2000, 749. Lippincott Williams & Wilkins, Philadelphia. 2nd ed. J.R. Harris, M.E. Lippmann, M. Morrow (Eds.).
7. Taylor C.W., Dalton W.S., Parrish P.R., Gleason M.C., Bellamy W.T., Thompson F.H., Roe D.J., Trent J.M. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br. J. Cancer 1991, 63(6):923-929.
8. Tsuruo T., Naito M., Tomida A., Fujita N., Mashima T., Sakamoto H., Haga N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003, 94(1):15-21.
9. Kruh G.D. Introduction to resistance to anticancer agents. Oncogene 2003, 22(47):7262-7264.
10. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
11. Chekhun V.F., Kulik G.I., Yurchenko O.V., Tryndyak V.P., Todor I.N., Luniv L.S., TregubovaT N.A., Pryzimirska V., Montgomery B., Rusetskaya N.V., Pogribny I.P. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Lett. 2006, 231(1):87-93.
12. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2(1):48-58.
13. Harbottle A., Daly A.K., Atherton K., Campbell F.C. Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int. J. Cancer 2001, 92(6):777-783.
14. Burgess D.J., Doles J., Zender L., Xue W., Ma B., McCombie W.R., Hannon G.J., Lowe S.W., Hemann M.T. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc. Natl. Acad. Sci. (PNAS) 2008, 105(26):9053-9058.
15. Davis J.M., Navolanic P.M., Weinstein-Oppenheimer C.R., Steelman L.S., Hu W., Konopleva M., Blagosklonny M.V., McCubrey J.A. Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin. Cancer Res. 2003, 9(3):1161-1170.
16. Iseri O.D., Kars M.D., Arpaci F., Gunduz U. Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins. Cancer Chemother. Pharmacol. 2010, 65(3):447-455.
17. Mehta K. High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. Int. J. Cancer 1994, 58(3):400-406.
18. Egawa C., Motomura K., Miyoshi Y., Takamura Y., Taguchi T., Tamaki Y., Inaji H., Koyama H., Noguchi S. Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers. Breast Cancer Res. Treat. 2003, 78(1):45-50.
19. Yang J.Y., Ha S.A., Yang Y.S., Kim J.W. p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance. BioMed Central (BMC) Cancer 2010, 10:388.
20. Chen V.Y., Posada M.M., Zhao L., Rosania G.R. Rapid doxorubicin efflux from the nucleus of drug-resistant cancer cells following extracellular drug clearance. Pharm. Res. 2007, 24(11):2156-2167.
21. Rajagopal A., Simon S.M. Subcellular localization and activity of multidrug resistance proteins. Mol. Biol. Cell 2003, 14(8):3389-3399.
22. Shen F., Chu S., Bence A.K., Bailey B., Xue X., Erickson P.A., Montrose M.H., Beck W.T., Erickson L.C. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J. Pharmacol. Exp. Ther. 2008, 324(1):95-102.
23. Ruggeri R.M., Sciacchitano S., Vitarelli E., Trimarchi F., Barresi G., Trovato M. Immunoexpression of multidrug-resistance protein 2 and cyclooxygenase 2 in medullary thyroid carcinomas. Arch. Pathol. Lab. Med. 2006, 130(7):1014-1019.
24. Belinsky M.G., Chen Z.S., Shchaveleva I., Zeng H., Kruh G.D. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002, 62(21):6172-6177.
25. Litman T., Brangi M., Hudson E., Fetsch P., Abati A., Ross D.D., Miyake K., Resau J.H., Bates S.E. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci. 2000, 113(Pt 11):2011-2021.
26. Dalton W.S., Scheper R.J. Lung resistance-related protein: determining its role in multidrug resistance. J. Natl. Cancer Inst. 1999, 91(19):1604-1605.
27. de Jong S., Kooistra A.J., de Vries E.G., Mulder N.H., Zijlstra J.G. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino) methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. Cancer Res. 1993, 53(5):1064-1071.
28. Volkova M., Palmeri M., Russell K.S., Russell R.R. Activation of the aryl hydrocarbon receptor by doxorubicin mediates cytoprotective effects in the heart. Cardiovasc. Res. 2011, 90(2):305-314.
29. Rodriguez-Antona C., Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006, 25(11):1679-1691.
30. Bray J., Sludden J., Griffin M.J., Cole M., Verrill M., Jamieson D., Boddy A.V. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br. J. Cancer 2010, 102(6):1003-1009.
31. Stavrovskaya A.A. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 2000, 65(1):95-106.
32. Muller M., Meijer C., Zaman G.J., Borst P., Scheper R.J., Mulder N.H., de Vries E.G., Jansen P.L. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. (PNAS) 1994, 91(26):13033-13037.
33. Seidegard J., Ekstrom G. The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics. Environ. Heal. Perspect. 1997, 105(Suppl. 4):791-799.
34. Kudoh K., Ramanna M., Ravatn R., Elkahloun A.G., Bittner M.L., Meltzer P.S., Trent J.M., Dalton W.S., Chin K.V. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 2000, 60(15):4161-4166.
35. Cowan K.H., Batist G., Tulpule A., Sinha B.K., Myers C.E. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc. Natl. Acad. Sci. (PNAS) 1986, 83(24):9328-9332.
36. Jančová P., Šiller M. Phase II Drug Metabolism. Topics on Drug Metabolism, InTech. 2012, 35-60. J. Paxton (Ed.).
37. Gartel A.L., Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther. 2002, 1(8):639-649.
38. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., Williams J., Lengauer C., Kinzler K.W., Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Investig. 1999, 104(3):263-269.
39. Barlow C., Brown K.D., Deng C.X., Tagle D.A., Wynshaw-Boris A. Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways. Nat. Genet. 1997, 17(4):453-456.
40. Teixeira C., Reed J.C., Pratt M.A. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 1995, 55(17):3902-3907.
41. Korsmeyer S.J., Shutter J.R., Veis D.J., Merry D.E., Oltvai Z.N. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin. Cancer Biol. 1993, 4(6):327-332.
42. Jope R.S., Yuskaitis C.J., Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem. Res. 2007, 32(4-5):577-595.
43. Karin M., Lin A. NF-kappaB at the crossroads of life and death. Nat. Immunol. 2002, 3(3):221-227.
44. Guo X., Hartley R.S. HuR contributes to cyclin E1 deregulation in MCF-7 breast cancer cells. Cancer Res. 2006, 66(16):7948-7956.
45. Harris S.L., Levine A.J. The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24(17):2899-2908.
46. Ohtani N., Yamakoshi K., Takahashi A., Hara E. The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. J. Investig. Med. 2004, 51(3-4):146-153.
47. Mai S., Fluri M., Siwarski D., Huppi K. Genomic instability in MycER-activated Rat1A-MycER cells. Chromosom. Res. 1996, 4(5):365-371.
48. Grassilli E., Ballabeni A., Maellaro E., Del Bello B., Helin K. Loss of MYC confers resistance to doxorubicin-induced apoptosis by preventing the activation of multiple serine protease- and caspase-mediated pathways. J. Biol. Chem. 2004, 279(20):21318-21326.
49. Fedier A., Steiner R.A., Schwarz V.A., Lenherr L., Haller U., Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int. J. Oncol. 2003, 22(5):1169-1173.
50. De Luca P., Vazquez E.S., Moiola C.P., Zalazar F., Cotignola J., Gueron G., Gardner K., De Siervi A. BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer. Mol. Cancer Res. 2011, 9(8):1078-1090.